Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study

[1] Koskinas KC(2016)Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients Circ Cardiovasc Interv 9 e003255-5

[2] Siontis GCM(1995)Fibrinogen and cardiovascular disease: historical introduction Eur Heart J 16 2-520

[3] Piccolo R(2000)Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease Eur Heart J 21 515-e134

[4] Franzone A(2007)Inflammation, atherosclerotic burden and cardiovascular prognosis Atherosclerosis 195 e126-1809

[5] Haynes A(1995)Fibrinogen, fibrin and the arterial wall Eur Heart J 16 21-1638

[6] Rat-Wirtzler J(2005)Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis JAMA 294 1799-281

[7] Silber S(2000)Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population Circulation 102 1634-3125

[8] Serruys PW(2017)Elevated baseline serum fibrinogen: effect on 2-year major adverse cardiovascular events following percutaneous coronary intervention J Am Heart Assoc 6 11-S124

[9] Pilgrim T(2019)Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study Cardiovasc Diabetol 18 52-S28

[10] Räber L(2020)Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease Cardiovasc Diabetol 19 36-245

[1] Koskinas KC(2016)Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients Circ Cardiovasc Interv 9 e003255-5

[2] Siontis GCM(1995)Fibrinogen and cardiovascular disease: historical introduction Eur Heart J 16 2-520

[3] Piccolo R(2000)Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease Eur Heart J 21 515-e134

[4] Franzone A(2007)Inflammation, atherosclerotic burden and cardiovascular prognosis Atherosclerosis 195 e126-1809

[5] Haynes A(1995)Fibrinogen, fibrin and the arterial wall Eur Heart J 16 21-1638

[6] Rat-Wirtzler J(2005)Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis JAMA 294 1799-281

[7] Silber S(2000)Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population Circulation 102 1634-3125

[8] Serruys PW(2017)Elevated baseline serum fibrinogen: effect on 2-year major adverse cardiovascular events following percutaneous coronary intervention J Am Heart Assoc 6 11-S124

[9] Pilgrim T(2019)Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study Cardiovasc Diabetol 18 52-S28

[10] Räber L(2020)Fibrinogen is associated with glucose metabolism and cardiovascular outcomes in patients with coronary artery disease Cardiovasc Diabetol 19 36-245